Deep Medicine Acquisition Corp.
Status: Deal Closed
U=S+R
R=S/10
| IPO Proceeds, $M | $126.50M |
|---|---|
| IPO Date | Oct 27, 2021 |
| CEO | Humphrey P. Polanen |
| Left Lead | I-Bankers Securities |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 12 + 3 + 6 + 6 + 6 |
| IPO Sector | Healthcare |
| IPO Geography | Global |
| Target Company | TruGolf |
| Deal Announced | Jul 13, 2022 |
| Deal Size, $M | $125.00M |
| Deal Sector | Consumer |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Jan 19, 2024 |
| Amendment Vote | Jan 26, 2024 |
| Closing Date | Jan 31, 2024 |
Formerly DMAQ
TRUG
| Price | $1.66 |
|---|---|
| Last closing price | $1.69 |
| H/L, today | $1.62 / $1.74 |
| Volume, today | 7,990 |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Deep Medicine Acquisition Corp.:
- Structure and cap table
- 9 directors & officers
- 42 filings and events
- 3 underwriters
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Humphrey P. Polanen | 72 | CEO and Chairman |
| Weixuan Luo | 48 | CFO |
| Ronald M. Razmi, MD | 51 | Director |
| Tina Spires | 44 | Director |
| HongLiang Ren | 41 | Director |
| Bryant E. Fong | 48 | Director |
| Marc A. Hamer | 48 | Director |
| Wanlei Miao | 37 | Director |
| John Chiang | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| I-Bankers Securities | BR | 8,400,000 | units |
| Dawson James | 1,600,000 | ||
| Ingalls & Snyder | 1,000,000 | ||
| 11,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| BCMA | 3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.
Filings
Sign in to view 42 filings.